The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated results from an ongoing phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via IT injection as monotherapy or combined with pembrolizumab in advanced solid tumors.
 
Jiaxin Niu
Consulting or Advisory Role - AstraZeneca; Beigene; Boehringer Ingelheim; Bristol Mers Squibb; Daiichi Sankyo; Exact Sciences; Immvira; Johnson & Johnson; Merck; Mirati Therapeutics; OncLive Clinical Congress Consultants; Takeda
 
Howard L. Kaufman
Employment - Ankyra Therapeutics
Leadership - Ankyra Therapeutics
Stock and Other Ownership Interests - Immuneering; Replimune
Honoraria - Society for Immunotherapy of Cancer
Consulting or Advisory Role - Castle Biosciences; Marengo Therapeutics; Midatech Pharma; Tatum Bioscience; Virogin Biotech
 
Ganessan Kichenadasse
Employment - Southern Oncology Clinical research Unit
Leadership - Southern Oncology Clinical research Unit
Research Funding - Aucentra Therapeutics; Henlius
 
Andrew Mark Haydon
Honoraria - Merck; Novartis; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
Speakers' Bureau - Bristol-Myers Squibb; Merck; Novartis
Expert Testimony - BMS
 
Minal A. Barve
Employment - Texas Oncology
Stock and Other Ownership Interests - Texas Oncology
Research Funding - Mary Crowley Research Center, Dallas Texas
 
Vinod Ganju
Honoraria - AstraZeneca; Roche/Genentech
 
Elizabeth Iannotti Buchbinder
Employment - Alexion Pharmaceuticals (I); Takeda (I)
Consulting or Advisory Role - Instil Bio; Iovance Biotherapeutics; Merck; Nektar; Novartis; Sanofi; Xilio Therapeutics
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals; Genentech/Roche; Lilly; Novartis
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Trovagene (Inst)
 
Weijia Pang
Employment - AstraZeneca; Immvira; MSD
 
Wenmin Fu
Employment - Immvira
 
Min Zhao
No Relationships to Disclose
 
John M. M. Kirkwood
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Ankyra Therapeutics; Applied Clinical Intelligence; AXIO Research; Becker Pharmaceutical Consulting; Cancer Network; Cancer Study Group; Checkmate Pharmaceuticals; DermTech; Fenix Group International; Harbour BioMed; Immunocore; iOnctura; Iovance Biotherapeutics; IQVIA; Istari Oncology; Jazz Pharmaceuticals; Magnolia Innovation; Merck; Natera; OncoCyte; OncoSec; PATHAI; Pfizer; Regeneron; Replimune; Scopus BioPharma; SR One Capital Management; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Harbour BioMed (Inst); Immunocore (Inst); Immvira (Inst); Iovance Biotherapeutics (Inst); Lion Biotechnologies (Inst); Novartis (Inst); Takeda (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Ankyra Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Iovance Biotherapeutics; Regeneron